Patent applications published 24 November 2010
Selected patent applications from the weekly European Patents Bulletin
- Solid formulation of low melting active compound
Arysta LifeScience 2252146*
- Combinations of phenylpyrroles and pyrion compounds
Janssen Pharmaceutica 2252147*
- Methods for treating bowel diseases
Salix Pharmaceuticals 2252148*
- A method for the production of fentanyl
Director General, Defence Research and Development Organisation, India 2252149*
- Selective opioid compounds
Alkermers 2252150*
- Quinolizidinone M1 receptor positive allosteric modulators
Merck Sharp & Dohme 2252151*
- B ring reduced-D ring oxidised tetrapyrollic photosensitisers for photodynamic therapy and tumour imaging
Health Research 2252153*
- Method for minimising the cytotoxicity of the effective agent in a compsn that is administered to a mammal or gets into contact with a mammal
Oy Granula 2252154*
- Method for minimising the cytotoxicity of the effective agent inhibiting the growth of microorganisms and for maximising the effect
Oy Granula 2252155*
- Parenteral formulations of dopamine agonists
VeroScience 2252259*
- Method for stabilisation of S-nitrosogluta-thione and compsns prepared by the same
Pharmagenix 2252260*
- Drug delivery system with stabilising effect
Bayer Schering Pharma 2252261*
- Method to enhance aqueous solubility of poorly soluble actives using methoxypolyethylene glycol
Dow Global Technologies 2252262*
- Galenic form for the oral transmucosal delivery of triptans
Perovitch, Philippe; Maury, Marc 2252263*
- Injectable biocompatible compsn
NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen 2252264*
- Injectable preparations and a process of preparation thereof
Marvel Lifesciences 2252265*
- Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents
Yissum Research Development Company of the Hebrew University of Jerusalem; Technion Research and Development Foundation 2252266*
- Lyophilised nanoemulsion
Merck Patent 2252267*
- Pulmonary formulations of triptans
Vectura 2252268*
- Casein particles encapsulating therapeutically active agents and uses thereof
Technion Research & Development Foundation 2252269*
- Formulations of flibanserin
Boehringer Ingelheim International 2252270*
- Dip coated compsns containing a starch having a high amylose content
McNeill-PPC 2252271*
- Gingival wafer
LTS Lohmann Therapie-Systeme 2252272*
- Solid pharmaceutical compsn comprising a non-peptide angiotensin II receptor antagonist and a diuretic
Ratiopharm 2252273*
- Compsn comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
The Curators of the University of Missouri 2252274*
- Templated open flocs of anisotropic particles for enhanced pulmonary delivery
Board of Regents, The University of Texas System 2252275*
- Methods for the treatment and prevention of age-related retinal dysfunction
University of Washington 2252276*
- Acetyl mimic compounds for the treatment of isoprenyl-S-cysteinyl methyltransferases
Signum Biosciences 2252277*
- Compounds for use in the treatment of neuropathic pain
Centre National de la Recherche Scientifique 2252278*
- Amino acid formulations comprising cysteine, methionine and/or serine for the prevention of paracetamol-induced liver damage
Velleja Research 2252279*
- Use of eicosopentaenoic acid and/or docosahexahenoic acid in women with endometriosis
Pharmanutra 2252280*
- Blood substitute solution
President and Fellows of Harvard College; The United States Government as represented by the Department of Veterans Affairs 2252281*
- Cosmetic and/or dermatological compsn
Université de la Méditerranée 2252282*
- Synthetic triterpenoids and methods of use in the treatment of disease
Reata Pharmaceuticals; Trustees of Dartmouth College 2252283*
- Pharmaceutical compsns of entacapone, levodopa and carbidopa with improved bioavailability
Wockhardt Research Centre 2252284*
- Abnormal intraocular pressure treatment
Horphag Research (Luxembourg) Holdings; Indena 2252285*
- Combination of bis-thiazolium salt or a precursor thereof and artemisinin or a derivative thereof for treating acute malaria
Sanofi-Aventis; Centre National de la Recherche Scientifique (CNRS); University of Montpellier II 2225286*
- Use of inhibitor of beta-lactam and its combination with beta-lactam antibiotics
LEK Pharmaceuticals 2252287*
- Treatment of protein folding disorders
Summit Corp 2252288*
- Combination therapy comprising SGLT inhibitors and DPP4 inhibitors
Mitsubishi Tanabe Pharma Corp 2252289*
- Pharmaceutical compsn for use in the treatment and/or the prevention of osteoarticular diseases
Bone Therapeutics 2252290*
- Pharmaceutical compsn
Takeda Pharmaceutical 2252291*
- Cardioplegia solution for cardiac surgery
President and Fellows of Harvard College; The United States Government as represented by the Department of Veterans Affairs 2252292*
- Kinase inhibitors and methods of use
Intellikine 2252293*
- Use of ranolazine for treating pain
Gilead Science 2252294*
- Use of ranolazine for the treatment of cardiovascular diseases
Gilead Palo Alto 2252295*
- 3H-[1,2,3]triazolo[4,5-D]pyrimidine compounds, their use as MTOR kinases and P13 kinase inhibitors, and their synthesis
Wyeth 2252296*
- Protective effect of high dose folate on myocardial ischaemia
Universiteit Antwerpen; Biomedbooster 2252297*
- Compsns and methods for treating lung cancer
Board of Regents of the University of Texas System 2252298*
- Fused pyridone M1 receptor positive allosteric modulators
Merck Sharp & Dohme 2252299*
- Use of 2,4-pyrimidinediamines for the treatment of atherosclerosis
Rigel Pharmaceuticals 2252300*